The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | HARMONi-GI1: 1L chemotherapy with durvalumab or ivonescimab for advanced BTC
James Harding, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the Phase III HARMONi-GI1 (NCT06591520) trial evaluating first-line (1L) ivonescimab plus chemotherapy versus durvalumab plus chemotherapy in patients with advanced biliary tract cancer (BTC). The trial met its primary endpoint in terms of overall survival with a median overall survival of 14.9 months with ivonescimab versus 12.1 months with durvalumab.The study’s secondary endpoints, including progression-free survival and response rate, were also positive, although with increased toxicity. Further analysis and longer follow-up are also needed, as well as more experience in diverse patient populations. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
